Leading the Way in Life Science Technologies

GEN Exclusives

More »

The Lists

More »
Oct 9, 2012

20 Top-Salaried Research University Leaders

Did your university president make the list?

20 Top-Salaried Research University Leaders

How do these figures compare to what biopharma CEOs or research institute leaders make? Check out GEN’s other lists to find out. [© 3desc - Fotolia.com]

  • #10. Morton O. Schapiro, Ph.D.

    President, Northwestern University

    $1,255,653 in FY 2010–2011

  • #9. Ronald J. Daniels, J.D.

    President, Johns Hopkins University

    $1,271,043 in FY 2010–2011

  • #8. C. L. Max Nikias, Ph.D.

    President, University of Southern California

    $1,316,059 in FY 2010–2011

  • #7. Amy Gutmann, Ph.D.

    President, University of Pennsylvania

    $1,462,742 in FY 2010–2011

  • #6. Robert J. Zimmer, Ph.D.

    President, University of Chicago

    $1,597,918 in FY 2010–2011

  • #5. Richard C. Levin, Ph.D.

    President, Yale University

    $1,616,066 in FY 2010–2011

  • #4. Lee C. Bollinger, Ph.D.

    President, Columbia University

    $1,932,931 in FY 2010–2011

  • #3. E. Gordon Gee, Ed.D.

    President, Ohio State University

    $1,992,221 in FY 2010–2011

  • #2. Nicholas S. Zeppos, J.D.

    Chancellor, Vanderbilt University

    $2,228,349 in FY 2010–2011

  • #1. Mark Stephen Wrighton, Ph.D.

    Chancellor, Washington University in St. Louis

    $2,268,837 in FY 2010–20116

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »